Metabolic Aspects of Five Commonly Used Non-Insulin Anti-Hyperglycemic Medications in Type 2 Diabetes
DOI:
https://doi.org/10.12970/2308-8044.2021.09.03Keywords:
Type 2 diabetes, metformin, sulfonylureas, glucagon-like peptide-1, dipeptyl peptidase-4 inhibitors, sodium glucose transporter-2 inhibitorsAbstract
Type 2 diabetes is a growing public health challenge while carrying a significant health burden for the patient suffering from it. The worldwide prevalence of diabetes in 2019 was estimated to be 9.3%. Fortunately, a number of drug classes are now available for the medical management of hyperglycemia in this disorder. Metformin and the sulfonylureas are time-tested medications that are effective and inexpensive as first-line medications. The incretin-based therapies, namely the glucagon-like peptide-1 agents and the dipeptyl peptidase-4 inhibitors, offer novel mechanisms of gut hormone and appetite modulation. The former combine weight loss and cardiovascular benefit with glycemic control. The sodium glucose cotransporter-2 inhibitors have a unique glycosuric action that lowers glucose while being of value in congestive heart failure. Almost all these classes of antihyperglcyemic agents can be used in various combinations with one another as well as with different insulin regimens. This article shows the chemical structures and summarizes the mechanistic and therapeutic aspects of the five main classes of noninsulin glucose-lowering medications approved for use in patients with type 2 diabetes.
References
Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 2020; 10: 14790. https://doi.org/10.1038/s41598-020-71908-9
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-2701. https://doi.org/10.2337/dci18-0033
Aroda VR, Edelstein SL, Goldberg RB, et al. Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101: 1754-1761. https://doi.org/10.1210/jc.2015-3754
Kim K-S, Lee B-W. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020; 26(4): 430-443. https://doi.org/10.3350/cmh.2020.0137
Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017; 60: 1620-1629. https://doi.org/10.1007/s00125-017-4337-9
Aggarwal N, Singla A, Mathieu C, et al. Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes Obes Metab 2018; 20: 463-467. https://doi.org/10.1111/dom.13104
Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56: 973-984. https://doi.org/10.1007/s00125-013-2856-6
UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. https://doi.org/10.1056/NEJMoa0802987
Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 2014; 16: 833-840. https://doi.org/10.1111/dom.12287
Khunti K, Chatterjee S, Gerstein HC, et al. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol 2018; pii: S2213-8587(18)30025-1.
Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394. https://doi.org/10.2337/dc06-1789
Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract 2015; 110: 75-81. https://doi.org/10.1016/j.diabres.2015.07.002
Wu S, Chai S, Yang J, et al. Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. Clin Ther 2017; 39: 1780-1789.e33. https://doi.org/10.1016/j.clinthera.2017.07.036
Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ 2016; 353: i2231. https://doi.org/10.1136/bmj.i2231
Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40: 284-286. https://doi.org/10.2337/dc15-1707
Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf 2016; 39: 401-407. https://doi.org/10.1007/s40264-016-0399-8
Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open 2014; 4: e005442. https://doi.org/10.1136/bmjopen-2014-005442
Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012; 34: 1247-1258.e22. https://doi.org/10.1016/j.clinthera.2012.04.013
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849-870. https://doi.org/10.1161/CIRCULATIONAHA.117.028136
Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016; 352: i610. https://doi.org/10.1136/bmj.i610
Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med 2017; 130(6S): S4-S17. https://doi.org/10.1016/j.amjmed.2017.04.004
Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2015; 17: 1065-1074. https://doi.org/10.1111/dom.12541
Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med 2016; 164: 102-113. https://doi.org/10.7326/M15-1432
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19: 524-536. https://doi.org/10.1111/dom.12849
Li Z, Zhang Y, Quan X, et al. Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS One 2016; 11: e0154206. https://doi.org/10.1371/journal.pone.0154206
Storgaard H, Cold F, Gluud LL, Vilsbøll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19: 906-908. https://doi.org/10.1111/dom.12885
Zhang X-L, Zhu Q-Q, Chen Y-H, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc 2018; 7: e007165. https://doi.org/10.1161/JAHA.117.007165
Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016; 11: e0166125. https://doi.org/10.1371/journal.pone.0166125
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128. https://doi.org/10.1056/NEJMoa1504720
Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19: 348-355. https://doi.org/10.1111/dom.12825
Tang H, Li D, Wang T, Zhai S, Song Y. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2016; 39: e123-e124. https://doi.org/10.2337/dc16-0885
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657. https://doi.org/10.1056/NEJMoa1611925
